Identification of empagliflozin-related hub genes in atherosclerosis and their correlations with immune infiltration: Network pharmacology and bioinformatics analyses.

ABSTRACT:

Background

Atherosclerosis (AS) is by far the most frequent underlying cause of atherosclerotic cardiovascular disease. Recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors stand out for their anti-atherosclerotic effects. The present study was conducted to explore the potential genetic and molecular mechanisms of empagliflozin, a selective SGLT2 inhibitor, in preventing AS, and the correlation of empagliflozin-related hub genes with immune cells.

Methods

In our study, pharmacology platforms were accessed to identify the empagliflozin-related genes (ERGs). AS datasets GSE100927 and GSE43292 were downloaded from the public GEO database to identify AS-differentially expressed genes (AS-DEGs). Furthermore, the empagliflozin-related DEGs (ERDEGs) were obtained by intersec

SUBMITTER: Rong Y 

PROVIDER: S-EPMC12810795 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature